INTRODUCTION
The Lesch-Nyhan syndrome is a bizarre, X-linked disease characterized by spasticity, choreoathetosis, selfmutilation, mental and growth retardation as well as hyperuricemia and hyperuricaciduria (1) which is due to a striking reduction of hypoxanthine-guanine phosphoribosyltransferase (HGPRT)' activity (2) . The discovery of a patient with the classical clinical syndrome in whom the reduced hypoxanthine-guanine phosphoribosyltransferase activity was due to an altered affinity for both substrates provided the first evidence for genetic heterogeneity in the Lesch-Nyhan syndrome and demonstrated that the mutation at least in this individual was on the structural gene coding for this enzyme (3) . Further studies of the mutant hypoxanthine-guanine phosphoribosyltransferase in cultured skin fibroblasts derived from affected patients provided further evidence for the existence of substantial genetic heterogeneity among patients with the syndrome (4) .
In the present study, we have demonstrated the presence of a low level of hypoxanthine-guanine phosphoribosyltransferase activity in circulating erythrocytes from 'Abbreviations used in this paper: CRM, cross-reactive material; GMP, guanosine monophosphate; HGPRT, hypoxanthine-guanine phosphoribosyltransferase; PP-ribose-P, tetrasodium phosphoribosylpyrophosphate.
The Journal of Clinical Investigation Volume 51 July 1972 some patients with the Lesch-Nyhan syndrome. The studies to be presented not only confirm the heterogeneity of the mutations on the structural gene coding for hypoxanthine-guanine phosphoribosyltransferase in patients with the Lesch-Nyhan syndrome but also describe an additional manifestation of the mutation in some patients: an accelerated half-life of enzyme activity in circulating erythrocytes. Despite the rapid loss of enzyme activity the mutant protein itself appears to exhibit normal stability.
METHODS
Hypoxanthine-8-'4C (3. 07 mCi/mmole) and guanine-8-'4C (6.05 mCi/mmole and 60 mCi/mmole) were purchased from New England Nuclear Corp., Boston, Mass. Tetrasodium phosphoribosylpyrophosphate (PP-ribose-P) was purchased from Sigma Chemical Co., St. Louis, Mo. Purified Noble Agar and Freund's complete adjuvant were purchased from Difco Laboratories, Detroit, Mich. Coomassie blue was purchased from Mann Research Labs, Inc., New York. Methyl phthalate and di-n-butyl phthalate came from Eastman Chemical Products, Inc., Kingsport, Tenn. All other reagents were of the highest quality commercially available.
Hypoxanthine-guanine phosphoribosyltransferase was assayed by a previously described radiochemical technique (5) . All hemolysates were dialyzed at 4VC against 1 mmi Tris buffer pH 7.4 for 2 hr before being assayed. Under the usual assay conditions the final reaction mixture contained 50 mmi Tris, 5 mm MgCl2, 1 mm PP-ribose-P, 0.1 mM purine base, and enzyme protein at pH 7.4 in a final volume of 100 /Al. The reaction was allowed to proceed for 20 min at 370C. Hypoxanthine-guanine phosphoribosyltransferase in hemolysate from 13 patients with the Lesch-Nyhan syndrome was assayed under the same conditions except guanine-8-'4C of high specific activity (60 mCi/mmole) was used and the incubation time was prolonged to 120 min. Hypoxanthineguanine phosphoribosyltransferase from patient E. S. unless otherwise indicated was assayed at a final concentration of 10 mM PP-ribose-P for 120 min. Identification of the product of the reaction as guanosine monophosphate (GMP) after incubation of mutant hemolysate with guanine-'4C, Mg, and PP-ribose-P was confirmed by ascending chromatography in 0.2 m ammonium formate pH 5.0 on Whatman DE81 (Rf 0.80), descending chromatography in butanol: acetic: water, 2: 1: 1 on Whatman 1 (Rf 0.19), and high voltage electrophoresis in 0.2 M citrate buffer, pH 3.2 and 0.05 M borate buffer pH 8.5 on Whatman 3 MM. The latter method was employed routinely for separating the products of the reaction. Background (150-250 cpm) was defined by the radioactivity migrating with carrier GMP after incubation of a reaction mixture which was complete except for the absence of PP-ribose-P.
Hypoxanthine-guanine phosphoribosyltransferase was purified to homogeneity from normal human (male) erythrocytes as described previously (6) . After DEAE-cellulose chromatography and heat treatment, preparative isoelectric focusing resulted in the isolation of three electrophoretic variants (pKi 5.6, 5. to an equal volume of serial dilutions of dialyzed hemolysate followed by incubation at 37'C for 30 min and then at 4VC for 16 hr. After centrifugation at 5000 g for 20 min at 4VC, the supernatant was assayed for hypoxanthine-guanine phosphoribosyltransferase activity. Incubation of hemolysate with serum obtained from the same rabbits before immunization and processed in a fashion identical to the antiserum did not inhibit hypoxanthine-guanine phosphoribosyltransferase activity. A low level of hypoxanthine-guanine phosphoribosyltransferase activity present in unimmunized and immunized sera was found to be related to the amount of hemolysis occurring during collection of the sample and was subtracted from the final incubation results.
A similar procedure was used to demonstrate the removal of the antibody to hypoxanthine-guanine phosphoribosyltransferase after incubation of mutant hemolysate with antiserum. Undiluted dialyzed mutant hemolysate (50 1l) was added to 50 Atl of antiserum and incubated at 37'C for 30 min and at 4°C for 16 hr. After centrifugation at 5000 g for 20 min at 4°C, a 50 Al portion of the supernatant was removed and assayed for its ability to inhibit hypoxanthine-guanine phosphoribosyltransferase as described above using 50 Al of a 1: 32 dilution of normal hemolysate.
Immunodiffusion and immunoelectrophoresis were performed as previously described (6) . The location of hypoxanthine-guanine phosphoribosyltransferase activity in the agar after immunoelectrophoresis was determined by cutting a companion slide (not exposed to antiserum) into 2 mm sections. Each section was placed in 200 ,l of 50 mm Tris buffer pH 7.4 at 4°C. After 18 hr a 50 ,l portion of the supernatant was assayed as previously described. A modification of the technique of quantitative immunodiffusion was employed to obtain an estimate of hypoxanthine-guanine phosphoribosyltransferase protein in preparations of normal and mutant hemolysates (7) . Serial dilutions of the sample containing hypoxanthine-guanine phosphoribosyltransferase protein were made in 50 mm Tris buffer at pH 7.4. Antigen and antiserum (monospecific for hypoxanthine-guanine phosphoribosyltransferase) wells were filled once. Precipitin patterns were allowed to develop for 24 hr at 4°C. Unprecipitated protein was then removed by washing with 0. acetic acid. The amount of antigen present in a sample was calculated from the greatest dilution at which a precipitin line was seen.
Erythrocyte fractionation studies were performed while the patients were on the Clinical Research Unit of Duke University Medical Center. All patients were on a diet essentially free of purines and were receiving allopurinol (300 mg/day) for at least 1 wk before the studies were performed. Fractionation of circulating erythrocytes was performed by a slight modification of the method of Danon and Marikovsky (8).2 After the final centrifugation, all erythrocyte fractions were washed three times with an equal volume of cold 154 mm NaCl, hemolyzed by freeze-thawing, dialyzed for 2 hr at 4°C against 1 mm Tris HCl, pH 7.4, and assayed as described above.
Protein was estimated by the method of Lowry, Rosenborough, Farr, and Randall using crystalline bovine serum albumin as a standard (9) . RESULTS Low levels of hypoxanthine-guanine phosphoribosyltransferase activity were reproducibly detected in hemolysates from five patients with the Lesch-Nyhan syndrome assayed with guanine-"C as substrate (Table I ). In one of these five hemolysates a similar level of hypoxanthineguanine phosphoribosyltransferase activity was detectable using hypoxanthine-'4C of relatively low specific activity as substrate. In the other four hemolysates hypoxanthineguanine phosphoribosyltransferase activity was substantially less (D. C.) or not detectable (W. E., J. K., and D. G.) using hypoxanthine-14C. Hemolysate from nine other patients with the Lesch-Nyhan syndrome which had been stored from 10 days to over 1 yr had no de2Beardmore, T. D., J. S. Cashman, and W. N. Kelley. 1972. Mechanism of allopurinol-mediated increase in enzyme activity in man. J. Clin. Invest. 51: 1823. tectable activity with either guanine or hypoxanthine as substrate.
Antisera produced against both an impure and a homogeneous preparation of normal erythrocyte hypoxanthine-guanine phosphoribosyltransferase were capable of inhibiting both the normal hypoxanthine-guanine phosphoribosyltransferase and the hypoxanthine-guanine phosphoribosyltransferase obtained from patient E. S. (Fig. 1) . Although not shown here, 100% inhibition of the catalytic activity of normal hypoxanthine-guanine instance showed a reaction of complete identity with each other and normal hypoxanthine-guanine phosphoribosyltransferase (Fig. 3) . Hypoxanthine-guanine phosphoribosyltransferase activity is relatively similar in erythrocytes of increasing density (age) obtained from normal subjects suggesting that the normal erythrocyte enzyme is stable in vivo. However, the mutant hypoxanthine-guanine phosphoribosyltransferase enzyme in circulating erythrocytes from at least three of the five patients studied with the LeschNyhan syndrome (J. K., D. C., and W. E.) appeared to be unstable when compared with the normal (Fig. 4) phoribosyltransferase activity in the most dense erythrocytes (specific gravity > 1.094) as compared with the least dense (specific gravity < 1.086) erythrocytes from four of the five patients with the Lesch-Nyhan syndrome, the amount of CRM was essentially the same in these two groups of cells in all five patients (Table II) . In addition, the amount of cross-reactive material did not change with prolonged storage of mutant hemolysate despite a marked decrease in hypoxanthine-guanine phosphoribosyltransferase activity.
Mutant Hypoxanthine-Guanine Phosphoribosyltransferase 
DISCUSSION
The characteristic clinical features of the Lesch-Nyhan syndrome were first recognized in 1964 (1) while the striking deficiency of hypoxanthine-guanine phosphoribosyltransferase in this syndrome was described in 1967 (2) . Since that time, many cases have been reported and in most studies essentially no hypoxanthine-guanine phosphoribosyltransferase activity has been found in erythrocyte lysates (10) (11) (12) (13) . This virtually complete absence of hypoxanthine-guanine phosphoribosyltransferase in patients with the Lesch-Nyhan syndrome has distinguished them from a group of subjects with a partial deficiency of hypoxanthine-guanine phosphoribosyltransferase (0.03 to 30% of normal) who have gout and hyperuricemia but are without serious neurologic disease (5, 14) . In the present study, we have found very low but reproducibly detectable levels of hypoxanthine-guanine phosphoribosyltransferase activity in erythrocytes of patients with the Lesch-Nyhan syndrome as have other investigators (15, 16) . However, the levels of hypoxanthine-guanine phosphoribosyltransferase activity in hemolysates from patients with the Lesch-Nyhan syndrome are still much lower than observed in most patients with gout who have the "partial" enzyme defect. The low levels of hypoxanthine-guanine phosphoribosyltransferase activity found in some hemolysates from patients with the Lesch-Nyhan syndrome are consistent with the low levels of hypoxanthine-guanine phosphoribosyltransferase activity found in cultured fibroblasts from affected individuals (17, 4) .
The stability of the hypoxanthine-guanine phosphoribosyltransferase activity in vivo was examined by density fractionation of intact circulating erythrocytes from normal subjects and patients with the Lesch-Nyhan syndrome. The observation that the hypoxanthine-guanine phosphoribosyltransferase activity in erythrocytes from normal subjects remains constant despite increasing cell age has also been reported by Fox, Wood, and O'Sullivan who used a technique nearly identical to the one used in the present study (18) . Also, Rubin, Balis, Piomelli, Berman, and Dancis using a different technique have noted a long half-life for normal hypoxanthine-guanine phosphoribosyltransferase activity (19) . The marked reduction of the hypoxanthine-guanine phosphoribosyltransferase activity in the most dense (oldest) erythrocytes from three of five patients with the Lesch-Nyhan syndrome as compared with the least dense (youngest) erythrocytes suggests that the mutant enzyme has an altered half-life in vivo in these three patients (J. K., D. C., and W. E.). This finding is perhaps comparable to previous studies in cultured fibroblasts from patients with the Lesch-Nyhan syndrome in which the hypoxanthine-guanine phosphoribosyltransferase enzyme from seven of eight mutant strains (including cell strains derived from J. K. and W. E.) studied was found to be abnormally labile to heat treatment (4) . Significantly, the patient E. S., whose hypoxanthine-guanine phos- (20, 21) . Material which cross-reacts with an antibody to normal hypoxanthine-guanine phosphoribosyltransferase was demonstrated in hemolysates from patients with the Lesch-Nyhan syndrome by three different techniques. Direct antibody-mediated inhibition of the catalytic activity of hypoxanthine-guanine phosphoribosyltransferase was shown for both the normal enzyme and the enzyme from patient E. S. which was the only mutant form of the enzyme with sufficient activity to allow this type of study. Preincubation of this antiserum with hemolysates from 14 different patients with the Lesch-Nyhan syndrome decreased the antibody-mediated inhibition of the normal hypoxanthine-guanine phosphoribosyltransferase. This indicates that in each of these hemolysates material was present which was capable of reacting with the hypoxanthine-guanine phosphoribosyltransferase antibody such that it was no longer free to inhibit the normal enzyme. Rubin, Dancis, Yip, Nowinski, and Balis have recently reported a similar finding in four patients with the Lesch-Nyhan syndrome (22) . In addition, immunodiffusion and immunoelectrophoresis using antiserum monospecific for normal hypoxanthine-guanine phosphoribosyltransferase provided independent confirmation of the presence of CRM in hemolysates from all 14 patients and indicated that each possessed a reaction of complete identity with the normal enzyme. From these studies it is apparent that the low levels of catalytic activity for hypoxanthine-guanine phosphoribosyltransferase in erythrocytes from patients with the Lesch-Nyhan syndrome are not due to a comparable deficiency of hypoxanthineguanine phosphoribosyltransferase protein.
The relatively short half-life of hypoxanthine-guanine phosphoribosyltransferase activity in at least three patients with the Lesch-Nyhan syndrome does not appear to represent an accelerated degradation of enzyme protein but rather an accelerated loss of enzyme function. This is suggested by the finding of normal quantities of CRM in hemolysate from all 14 patients with the LeschNyhan syndrome. More direct evidence for this hypothesis is provided by the finding of a constant amount of CRM in young and old erythrocytes from patients with the Lesch-Nyhan syndrome as well as from normal subjects. To our knowledge this phenomenon has not been shown previously for a mammalian protein. However, it is similar in some respects to the studies of Gershon and Gershon who used immunochemical techniques to identify two different pools of isocitrate lyase protein in nematodes; one enzymatically active, the other inactive (23) . With increasing age the latter pool grew larger at the expense of the former. The authors concluded that this represented a postgenetic modification leading to the inactivation of a large proportion of the enzyme molecules in the older organism.
The finding of hypoxanthine-guanine phosphoribosyltransferase protein with relatively labile activity in the Lesch-Nyhan syndrome may be of therapeutic importance. The possibility exists that the defective hypoxanthine-guanine phosphoribosyltransferase protein could be activated or that the active enzyme could be stabilized. This approach to therapy could be assessed serially by direct assay of hypoxanthine-guanine phosphoribosyltransferase in circulating erythrocytes separated by their density.
